Nkarta Clinical Trial Data
Nkarta announced positive initial clinical data from its Ntrust program evaluating NKX019, an allogeneic CAR NK cell therapy, for myositis and systemic sclerosis. In the 4 billion cells per dose cohort, 83% of myositis patients achieved moderate or major responses, while 86% of systemic sclerosis patients achieved an rCRISS-25 response or greater. The therapy demonstrated a favorable safety profile with no cases of CRS, ICANS, or GvHD across 40 treated patients.